title: Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor.
authors.affiliation: Kantonsspital St Gallen, Department of Medical Oncology, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland. christian.rothermundt@kssg.ch
authors.forename: Christian
authors.initials: C
authors.lastname: Rothermundt
authors.forename: Silke
authors.initials: S
authors.lastname: Gillessen
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D017311:Amlodipine / Q000008:administration & dosage; D000799:Angioedema / Q000139:chemically induced* / Q000188:drug therapy; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism; D004334:Drug Administration Schedule; D004347:Drug Interactions; D000068338:Everolimus; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017706:Lisinopril / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000305:Adrenal Cortex Hormones; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D017311:Amlodipine; D000068338:Everolimus; D017706:Lisinopril; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus